The deubiquitinase CYLD is a specific checkpoint of the STING antiviral signaling pathway

PLoS Pathog. 2018 Nov 2;14(11):e1007435. doi: 10.1371/journal.ppat.1007435. eCollection 2018 Nov.

Abstract

Stimulator of interferon genes (STING) is critical for cytosolic DNA-triggered innate immunity. STING is modified by several types of polyubiquitin chains. Here, we report that the deubiquitinase CYLD sustains STING signaling by stabilizing the STING protein. CYLD deficiency promoted the K48-linked polyubiquitination and degradation of STING, attenuating the induction of IRF3-responsive genes after HSV-1 infection or the transfection of DNA ligands. Additionally, CYLD knockout mice were more susceptible to HSV-1 infection than their wild-type (WT) littermates. Mechanistically, STING translocated from the ER to the Golgi upon HSV-1 stimulation; CYLD partially accumulated with STING and interacted selectively with K48-linked polyubiquitin chains on STING, specifically removing the K48-linked polyubiquitin chains from STING and ultimately boosting the innate antiviral response. Our study reveals that CYLD is a novel checkpoint in the cGAS-STING signaling pathway and sheds new light on the dynamic regulation of STING activity by ubiquitination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / metabolism
  • Cysteine Endopeptidases / metabolism
  • Deubiquitinating Enzyme CYLD / metabolism*
  • Golgi Apparatus / metabolism
  • HEK293 Cells
  • HeLa Cells
  • Herpesvirus 1, Human / metabolism
  • Humans
  • Immunity, Innate
  • Membrane Proteins / metabolism*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Polyubiquitin / genetics
  • Signal Transduction
  • Ubiquitination

Substances

  • Antiviral Agents
  • Membrane Proteins
  • STING1 protein, human
  • Sting1 protein, mouse
  • Polyubiquitin
  • CYLD protein, human
  • CYLD protein, mouse
  • Deubiquitinating Enzyme CYLD
  • Cysteine Endopeptidases

Grants and funding

This study is supported by National Key R&D Program of China (2016YFA0501800, 2017YFA0504501), National Natural Science Foundation of China (31730018, 81672029, 81602325, 31430055, 31190062), State Key Laboratory of Natural Medicine (SKLNMZZCX201802), the National New Drug Innovation Major Project of China (2017ZX09309027). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.